NeuroVive Pharmaceutical

CEO:  Erik Kinnman


NeuroVive Pharmaceutical AB was founded in 2000 with the aim of commercializing cyclosporine-based drugs for the treatment of acute traumatic conditions. Cyclosporine is able to reduce the level of secondary tissue damage following a traumatic injury by mitochondrial protection. NeuroVive went public in 2008 with an IPO on the Swedish AktieTorget exchange.

Share Button